RA
CRL icon

Rise Advisors’s Charles River Laboratories CRL Stock Holding History

Rise Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-63
Closed -$9.86K – 401
2025
Q3 		$9.86K Hold
63
– – ﹤0.01% 1005
2025
Q2 		$9.56K Hold
63
– – ﹤0.01% 1019
2025
Q1 		$9.48K Buy
63
+13
+26% +$2.18K ﹤0.01% 1004
2024
Q4 		$9.23K Hold
50
– – ﹤0.01% 996
2024
Q3 		$9.85K Hold
50
– – ﹤0.01% 1011
2024
Q2 		$10.3K Hold
50
– – 0.01% 1009
2024
Q1 		$13.5K Buy
+50
New +$11.9K 0.01% 926

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Rise Advisors's CRL Position: Q4 2025 in Review

Rise Advisors sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 63 shares — an estimated $9.86K sold.

Rise Advisors first reported a position in CRL in Q1 2024 and held it in 7 quarters. The position peaked at $13.5K in Q1 2024. 583 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • Rise Advisors reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 63 Charles River Laboratories shares in Q4 2025, an estimated $9.86K.
  • Rise Advisors first reported a position in Charles River Laboratories in Q1 2024 and held it in 7 quarters.
  • Rise Advisors's Charles River Laboratories position peaked at $13.5K in Q1 2024.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.